SAN DIEGO, April 10 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today that it has appointed Robert “Chip” Schooley, M.D., to its Clinical and Scientific Advisory Board.
“We are very fortunate to have someone of Dr. Schooley’s stature joining our Clinical and Scientific Advisory Board,” said Devron R. Averett, Ph.D., Anadys’ Chief Scientific Officer. “Chip is a leading AIDS clinical investigator who led the National Institute of Allergy and Infectious Diseases, AIDS Clinical Trials Group from 1995-2002. His outstanding expertise in viral diseases and his input along with our entire team of clinical and scientific advisors will be especially valuable as we optimize and advance our discovery program in a novel mechanism in HIV.”
Robert Schooley, M.D., is Professor and Head of the Division of Infectious Diseases of the University of California, San Diego. He has served as Chair of the National Institutes of Health’s AIDS and Related Retrovirus 1 Study Section and as Chair of the Executive Committee of the National Institute of Allergy and Infectious Diseases, AIDS Clinical Trials Group (ACTG). Dr. Schooley is currently a Member of the American Association for the Advancement of Science; American Society for Clinical Investigation; American Society for Microbiology; Clinical Immunology Society; and Association of American Physicians. He is also a Fellow of the Infectious Diseases Society of America.
Dr. Schooley received his M.D. from the Johns Hopkins University School of Medicine and his postdoctoral training at the National Institutes of Health and Massachusetts General Hospital, Harvard University.
Dr. Schooley joins current members: Spyros Artavanis-Tsakonas, Ph.D., Frank Chisari, M.D., David P. Clough, Ph.D., Jason S. Fisherman, M.D., Anna Suk-Fong Lok, M.D., John G. McHutchison, M.D., FRACP, K.C. Nicolaou, Ph.D., and Douglas D. Richman, M.D., Chairman of the Clinical and Scientific Advisory Board.
About Anadys
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of hepatitis, other serious infections, and cancer. The Company has core expertise in Toll-Like Receptor- based small molecule therapeutics and structure-based drug design coupled with medicinal chemistry. Anadys’ clinical development programs include ANA975 for the treatment of hepatitis C virus (HCV) and hepatitis B virus (HBV), and ANA380 for the treatment of HBV. In addition, Anadys’ therapeutic platform is designed to advance a strong and continual pipeline of drug candidates into the clinic.
Safe Harbor Statement
Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, references to the anticipated impact that Dr. Schooley and Anadys’ other clinical and scientific advisors will have on Anadys’ plans to optimize and advance its discovery program in a novel mechanism in HIV. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys’ actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. In particular, the results of initial clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will have favorable results in future clinical trials or receive regulatory approval. In addition, Anadys’ results may be affected by risks related to its collaborative relationships with Novartis and LG Life Sciences, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, the level of effort that its collaborative partners devote to development and commercialization of its product candidates, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. These and other factors that may cause actual results to differ are more fully discussed in the “Risk Factors” section of Anadys’ Form 10-K for the year ended December 31, 2005. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Anadys Pharmaceuticals, Inc.
CONTACT: Vince Reardon, Sr. Director, Investor Relations & CorporateCommunications of Anadys Pharmaceuticals, Inc., +1-858-530-3653,vreardon@anadyspharma.com
Web site: http://www.anadyspharma.com/
